Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

Silvia Nozza, Laura Galli, Francesca Visco, Alessandro Soria, Filippo Canducci, Stefania Salpietro, Nicola Gianotti, Alba Bigoloni, Liviana Della Torre, Giuseppe Tambussi, Adriano Lazzarin, Antonella Castagna

Research output: Contribution to journalArticle

Abstract

We prospectively evaluated 28 triple-class experienced HIV-1-infected patients harbouring R5 virus, who received maraviroc, raltegravir and etravirine. By on-treatment analysis, 26 (92%) had less than 50 copies HIV-RNA/ml at week 48. The median (interquartile range) 48-week increase in CD4 cell counts was 267 (136-355) cells/μl. Three serious adverse events occurred: one recurrence of mycobacterial spondylodiscitis, one anal cancer, one Hodgkin lymphoma. Although long-term safety needs further study, this protease inhibitor and nucleoside analogue-sparing regimen showed sustained efficacy.

Original languageEnglish
Pages (from-to)924-928
Number of pages5
JournalAIDS (London, England)
Volume24
Issue number6
DOIs
Publication statusPublished - Mar 2010

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience'. Together they form a unique fingerprint.

  • Cite this